Matteo Levisetti
Chief Tech/Sci/R&D Officer presso CUE BIOPHARMA, INC.
Patrimonio netto: 17 445 $ in data 31/03/2024
Profilo
Matteo Levisetti's career history includes current and former positions as well as his education.
Currently, he is the Chief Medical Officer at Cue Biopharma, Inc. Prior to this, he held the position of Chief Medical Officer at DNAtrix, Inc. from 2019 to 2021.
Additionally, he served as the Executive Director-Clinical Development at Mirati Therapeutics, Inc. from 2016 to 2017 and as the Chief Medical Officer at Dauntless Pharmaceuticals, Inc. from 2017 to 2018.
He also worked as the Global Head & VP-Translational Medicine at Roche Pharmaceuticals, Inc. Furthermore, he has experience as an Assistant Professor at Washington University School of Medicine.
Dr. Levisetti obtained his doctorate degree from Pritzker School of Medicine in 1996.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
CUE BIOPHARMA, INC.
0.02% | 06/03/2024 | 9 230 ( 0.02% ) | 17 445 $ | 31/03/2024 |
Posizioni attive di Matteo Levisetti
| Società | Posizione | Inizio |
|---|---|---|
| CUE BIOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 22/02/2021 |
Precedenti posizioni note di Matteo Levisetti
| Società | Posizione | Fine |
|---|---|---|
DNAtrix, Inc.
 DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Chief Tech/Sci/R&D Officer | 01/01/2021 |
Dauntless Pharmaceuticals, Inc.
 Dauntless Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Dauntless Pharmaceuticals, Inc. develops specialty therapeutics via a one-asset, one-company model that is structured to facilitate operational efficiencies. The company was founded by Joel F. Martin and Michael F. Powell in May 2015 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01/06/2018 |
| MIRATI THERAPEUTICS | Chief Tech/Sci/R&D Officer | 01/05/2017 |
| Washington University School of Medicine | Corporate Officer/Principal | - |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Corporate Officer/Principal | - |
Formazione di Matteo Levisetti
| Pritzker School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CUE BIOPHARMA, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Commercial Services |
DNAtrix, Inc.
DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Electronic Technology |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Dauntless Pharmaceuticals, Inc.
Dauntless Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Dauntless Pharmaceuticals, Inc. develops specialty therapeutics via a one-asset, one-company model that is structured to facilitate operational efficiencies. The company was founded by Joel F. Martin and Michael F. Powell in May 2015 and is headquartered in San Diego, CA. | Retail Trade |
- Borsa valori
- Insiders
- Matteo Levisetti
